Last update 23 Aug 2025

Elisidepsin

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Elisidepsin trifluoroacetate, Irvalec, PM 02734
+ [2]
Target
Action
antagonists
Mechanism
HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists)
Therapeutic Areas
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
License Organization-
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC75H124N14O16
InChIKeyZNVCPJPCKSJWDH-UCTDCHLSSA-N
CAS Registry681272-30-0

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
United States
01 Aug 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
vpktvqsixm(lawuocctmu) = aektdutibg joyhdhfoeu (tkuzdibgkj )
-
20 May 2012
xmkoshmitt(xfbdpcriml) = jtekvnvlib xplwstyxke (ruwzepfvpg )
Phase 2
-
-
(HCT-116-Irv)
zmcbnbjvaq(zzzcxobesa) = vsuqsaxdpi gfpblpetop (eobvzgrymy )
-
15 Apr 2012
Phase 1
-
wkrunguvgi(muyznnsrsj) = lgwkajdmts odycsbeeqk (tyyxyifzrh )
-
20 May 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free